Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38085056)

  • 1. Neuroblastoma and Glioblastoma Cases With Amplified Oncogenes Have Reduced Numbers of Tumor-Resident Adaptive Immune Receptor Recombinations.
    Dabkowski TR; Varkhedi M; Song JJ; Gozlan EC; Blanck G
    JCO Precis Oncol; 2023 Sep; 7():e2300057. PubMed ID: 38085056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53.
    Yi JS; Sias-Garcia O; Nasholm N; Hu X; Iniguez AB; Hall MD; Davis M; Guha R; Moreno-Smith M; Barbieri E; Duong K; Koach J; Qi J; Bradner JE; Stegmaier K; Weiss WA; Gustafson WC
    Neoplasia; 2021 Jun; 23(6):624-633. PubMed ID: 34107377
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MYCN induces neuroblastoma in primary neural crest cells.
    Olsen RR; Otero JH; García-López J; Wallace K; Finkelstein D; Rehg JE; Yin Z; Wang YD; Freeman KW
    Oncogene; 2017 Aug; 36(35):5075-5082. PubMed ID: 28459463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Copy number gain of MYCN gene is a recurrent genetic aberration and favorable prognostic factor in Chinese pediatric neuroblastoma patients.
    Wang M; Zhou C; Cai R; Li Y; Gong L
    Diagn Pathol; 2013 Jan; 8():5. PubMed ID: 23320395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MYCN controls an alternative RNA splicing program in high-risk metastatic neuroblastoma.
    Zhang S; Wei JS; Li SQ; Badgett TC; Song YK; Agarwal S; Coarfa C; Tolman C; Hurd L; Liao H; He J; Wen X; Liu Z; Thiele CJ; Westermann F; Asgharzadeh S; Seeger RC; Maris JM; Guidry Auvil JM; Smith MA; Kolaczyk ED; Shohet J; Khan J
    Cancer Lett; 2016 Feb; 371(2):214-24. PubMed ID: 26683771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detection of amplified DNA sequences by reverse chromosome painting using genomic tumor DNA as probe.
    Joos S; Scherthan H; Speicher MR; Schlegel J; Cremer T; Lichter P
    Hum Genet; 1993 Feb; 90(6):584-9. PubMed ID: 8383093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MYCN is amplified during S phase, and c‑myb is involved in controlling MYCN expression and amplification in MYCN‑amplified neuroblastoma cell lines.
    Aygun N; Altungoz O
    Mol Med Rep; 2019 Jan; 19(1):345-361. PubMed ID: 30483774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic copy number alterations are associated with EGFR amplification and shortened survival in patients with primary glioblastoma.
    Muñoz-Hidalgo L; San-Miguel T; Megías J; Monleón D; Navarro L; Roldán P; Cerdá-Nicolás M; López-Ginés C
    Neoplasia; 2020 Jan; 22(1):10-21. PubMed ID: 31751860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALK is a MYCN target gene and regulates cell migration and invasion in neuroblastoma.
    Hasan MK; Nafady A; Takatori A; Kishida S; Ohira M; Suenaga Y; Hossain S; Akter J; Ogura A; Nakamura Y; Kadomatsu K; Nakagawara A
    Sci Rep; 2013 Dec; 3():3450. PubMed ID: 24356251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Druggable epigenetic suppression of interferon-induced chemokine expression linked to
    Seier JA; Reinhardt J; Saraf K; Ng SS; Layer JP; Corvino D; Althoff K; Giordano FA; Schramm A; Fischer M; Hölzel M
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34016720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of MYCN amplification in neuroblastoma at diagnosis, treatment, relapse, and metastasis.
    Marrano P; Irwin MS; Thorner PS
    Genes Chromosomes Cancer; 2017 Jan; 56(1):28-41. PubMed ID: 27465929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MYCN amplified neuroblastoma requires the mRNA translation regulator eEF2 kinase to adapt to nutrient deprivation.
    Delaidelli A; Negri GL; Jan A; Jansonius B; El-Naggar A; Lim JKM; Khan D; Oo HZ; Carnie CJ; Remke M; Maris JM; Leprivier G; Sorensen PH
    Cell Death Differ; 2017 Sep; 24(9):1564-1576. PubMed ID: 28574509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct Targeting of
    Yoda H; Inoue T; Shinozaki Y; Lin J; Watanabe T; Koshikawa N; Takatori A; Nagase H
    Cancer Res; 2019 Feb; 79(4):830-840. PubMed ID: 30584073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastoma.
    Hallett RM; Seong AB; Kaplan DR; Irwin MS
    Mol Oncol; 2016 Nov; 10(9):1461-1472. PubMed ID: 27599694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MIAT Is an Upstream Regulator of NMYC and the Disruption of the MIAT/NMYC Axis Induces Cell Death in
    Feriancikova B; Feglarova T; Krskova L; Eckschlager T; Vicha A; Hrabeta J
    Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33806217
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BLM germline and somatic PKMYT1 and AHCY mutations: Genetic variations beyond MYCN and prognosis in neuroblastoma.
    Novak EM; Halley NS; Gimenez TM; Rangel-Santos A; Azambuja AM; Brumatti M; Pereira PL; Vince CS; Giorgi RR; Bendit I; Cristofani LM; Odone-Filho V
    Med Hypotheses; 2016 Dec; 97():22-25. PubMed ID: 27876123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical significance of MYCN amplification in patients with high-risk neuroblastoma.
    Lee JW; Son MH; Cho HW; Ma YE; Yoo KH; Sung KW; Koo HH
    Pediatr Blood Cancer; 2018 Oct; 65(10):e27257. PubMed ID: 29797634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MYCN drives glutaminolysis in neuroblastoma and confers sensitivity to an ROS augmenting agent.
    Wang T; Liu L; Chen X; Shen Y; Lian G; Shah N; Davidoff AM; Yang J; Wang R
    Cell Death Dis; 2018 Feb; 9(2):220. PubMed ID: 29445162
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thymidylate synthase inhibitor raltitrexed can induce high levels of DNA damage in MYCN-amplified neuroblastoma cells.
    Yamashita K; Kiyonari S; Tsubota S; Kishida S; Sakai R; Kadomatsu K
    Cancer Sci; 2020 Jul; 111(7):2431-2439. PubMed ID: 32415892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MYCN protein stability is a better prognostic indicator in neuroblastoma.
    Yang Y; Zhao J; Zhang Y; Feng T; Yv B; Wang J; Gao Y; Yin M; Tang J; Li Y
    BMC Pediatr; 2022 Jul; 22(1):404. PubMed ID: 35820898
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.